NDAOPHTHALMICSUSPENSION/DROPS
Approved
Mar 2024
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
13
Data completeness
5/8 — Partial
BYQLOVI (clobetasol propionate) by R-Pharm US is corticosteroids, clobetasol propionate has anti-inflammatory, antipruritic, and vasoconstrictive properties. First approved in 2024.
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BYQLOVI is a topical ophthalmic suspension of clobetasol propionate, a potent corticosteroid approved by the FDA in March 2024. It treats inflammatory and pruritic ophthalmic conditions by inhibiting phospholipase A2, thereby reducing prostaglandin and leukotriene-mediated inflammation. The drug is indicated for patients with ocular inflammation requiring potent topical corticosteroid therapy.
Growth9.9 years to LOE
Recent FDA approval positions BYQLOVI in early commercial growth phase with expanding team buildout expected across field and marketing functions.
Mechanism of Action
corticosteroids, clobetasol propionate has anti-inflammatory, antipruritic, and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A 2 inhibitory…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (13)
Clobetasol Propionate Ophthalmic Nanoemulsion, 0.05% in the Treatment of Inflammation After Cataract Surgery in Pediatric Population
Started Dec 2022
60 enrolled
Cataracts Infantile
Comparative Efficacy of Tacrolimus and Clobetasol Propionate in Alopecia Areata
Started Nov 2022
70 enrolled
Alopecia Areata
Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-1)
Started Jun 2020
250 enrolled
Cataract
Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-2)
Started Jun 2020
215 enrolled
Cataract
Subject Reported Target-lesion Numeric Rating Scale Evaluation by Subjects With Plaque Psoriasis Treated With Clobex® (Clobetasol Propionate) Spray 0.05%
Started Jul 2013
28 enrolled
Plaque Psoriasis
Worked on BYQLOVI at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.